Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select... see more

TSX:GUD - Post Discussion

Knight Therapeutics Inc > OAN network coverage of Biogen approval
View:
Post by Stockoman1 on Jun 09, 2021 8:05pm

OAN network coverage of Biogen approval

OAN  covered Biogen approval with interview of one patient who had been using for a month or so he said it was helping in some ways .  Medical experts  in Britain not entirely convinced and  want some proof. Doctors skepttcal........long road ahead
Comment by Chianchin on Jun 10, 2021 5:13am
Naturally the bombastic GUD"s biased loosing promoters who want to recover from their lost fortunes know better than the FDA scientist. I suppose if their Granddad or mon is suffering from Alzheimer’s they will give them GUD’s drug and not Biogen’s so they can quickly inherit lots $$$ to cover losses from  their investment in GUD. 
Comment by MrMugsy on Jun 10, 2021 9:44am
Yes - agreed.  The brain is a complex place.  We have a long way to go to find a cure.  Until then, we're stuck with few options for Alzheimer's patients. I listened to ATE's CEO speak yesterday and he brought up Alzheimer's. He's convinced that inflammation likely plays a role in Alzheimer's/Parkinson's diseases. We also know H2S is deficient in ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities